Loading quotes...

Forecast

The analysts' average price target is €16.11 (+186.65%). The median is €15.50 (+175.80%).

Buy
  8
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Immatics plans $150m capital increase; Goldman Sachs reiterates buy recommendation

    Immatics announced a guaranteed capital increase of $150 million with the issuance of 12,945,916 shares and 4,315,304 pre‑funded warrants at $8.69 each. The stock rose premarket to $9.10 after the company released its Q2 interim results. Goldman Sachs confirmed its "Buy" recommendation in early trading, and analysts largely see a "Strong Buy" with an average 12‑month price target of $17–19. » More on de.investing.com


  • TD Cowen highlights Immatics as pharma favorite for 2026

    TD Cowen rates Immatics as "Buy" and names the company among its top SMIDCAP ideas for 2026. The focus is on the PRAME-directed cell therapy anzu-cel, for which several catalysts are expected in the second half of the year, including the phase‑III SUPRAME trial. Analysts see reduced risk due to strong phase‑Ib data (ORR 57%, DCR 93%, median PFS 6.0 months) and note potential advantages over Amtagvi in efficacy, manufacturing and safety. TD Cowen estimates anzu-cel's annual revenue potential at about USD 1.6 billion by 2035 and points to upcoming data updates at ASCO 2026. » More on de.investing.com


  • Immatics invites to annual general meeting on June 18 in Amsterdam

    Immatics convenes its ordinary annual general meeting for June 18, 2026 at 16:00 CEST at the offices of NautaDutilh, Beethovenstraat 400, Amsterdam. Shareholders will receive the notice of meeting, agenda, proxy form and the form for the "2026 Immatics stock options & incentive plan." The announcement was also published in a filing with the U.S. Securities and Exchange Commission (SEC). » More on de.investing.com

Financials

In the last quarter, Immatics had revenue of €6.92m and net profit of -€76.02m
(EUR) September 2026
YoY
Revenue 6.92m 33.47%
Gross profit 6.92m 33.47%
Net profit -76.02m 50.40%
EBITDA -73.35m 54.83%

Fundamentals

Metric Value
Market capitalization
€857.99m
Number of shares
149.64m
52-week high/low
€11.31 - €5.52
Dividends No
Beta
1.35
P/E ratio
-3.42
PEG ratio
0.04
P/B ratio
1.88
P/S ratio
19.69

Company profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in TĂĽbingen, Germany.

Name
Immatics
CEO
Harpreet Singh
Headquarters TĂĽbingen, bw
Germany
Website
Sector
Health Care
Industry
Biotechnology
IPO
12/12/2018
Employees 656

Ticker symbols

Exchange Symbol
NASDAQ
IMTX
Frankfurt
4A3.F
DĂĽsseldorf
4A3.DU
MĂĽnchen
4A3.MU
🍪

Parqet  uses cookies. Learn more